{
    "clinical_study": {
        "@rank": "33353", 
        "arm_group": [
            {
                "arm_group_label": "botulinum toxin type A", 
                "arm_group_type": "Experimental", 
                "description": "Botulinum toxin type A injected at Day 1, followed by another treatment after a minimum of 12 weeks has elapsed from previous treatment (if applicable). Beginning on Day 1, one solifenacin placebo capsule taken orally once daily for up to 27 weeks with dose modifications as per protocol (if applicable)."
            }, 
            {
                "arm_group_label": "solifenacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo (normal saline) injected at Day 1, followed by another treatment after a minimum of 12 weeks has elapsed from previous treatment (if applicable). Beginning on Day 1, one solifenacin capsule taken orally once daily for up to 27 weeks with dose modifications as per protocol (if applicable)."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (normal saline) injected at Day 1, followed by another treatment after a minimum of 12 weeks has elapsed from previous treatment (if applicable). Beginning on Day 1, one solifenacin placebo capsule taken orally once daily for up to 27 weeks with dose modifications as per protocol (if applicable)."
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the efficacy and safety of botulinum toxin type A  (BOTOX\u00ae) in patients\n      with overactive bladder (OAB) and urinary incontinence."
        }, 
        "brief_title": "A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Overactive Bladder", 
            "Urinary Incontinence"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Incontinence", 
                "Urinary Bladder, Overactive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptoms of Overactive Bladder (OAB) (frequency/urgency) with urinary incontinence\n             for at least 6 months\n\n          -  Inadequate response or limiting side effects with anticholinergics for the treatment\n             of OAB\n\n        Exclusion Criteria:\n\n          -  Overactive Bladder caused by neurological condition\n\n          -  Patient has predominance of stress incontinence\n\n          -  Use of anticholinergics or other medications to treat OAB symptoms in the 7 days\n             prior to screening\n\n          -  Previous use of solifenacin\n\n          -  History or evidence of pelvic or urological abnormality\n\n          -  Previous use of any botulinum toxin of any serotype for any urological condition\n\n          -  Previous use of any botulinum toxin of any serotype for any non-urological condition\n             within 12 weeks of randomization\n\n          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "345", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767519", 
            "org_study_id": "191622-125"
        }, 
        "intervention": [
            {
                "arm_group_label": "botulinum toxin type A", 
                "description": "Botulinum toxin type A injected at Day 1, followed by another treatment after a minimum of 12 weeks has elapsed from previous treatment (if applicable).", 
                "intervention_name": "botulinum toxin type A", 
                "intervention_type": "Biological", 
                "other_name": [
                    "BOTOX\u00ae", 
                    "onabotulinumtoxinA"
                ]
            }, 
            {
                "arm_group_label": "solifenacin", 
                "description": "Beginning on Day 1, one capsule taken orally once daily for up to 27 weeks with dose modifications as per protocol (if applicable).", 
                "intervention_name": "solifenacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "solifenacin", 
                    "placebo"
                ], 
                "description": "Placebo (normal saline) injected at Day 1, followed by another treatment after a minimum of 12 weeks has elapsed from previous treatment (if applicable).", 
                "intervention_name": "placebo (normal saline)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "botulinum toxin type A", 
                    "placebo"
                ], 
                "description": "Beginning on Day 1, one capsule taken orally once daily for up to 27 weeks with dose modifications as per protocol (if applicable).", 
                "intervention_name": "solifenacin placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins", 
                "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague 6", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "Czech Republic", 
                "France", 
                "Germany", 
                "Poland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Episodes of Urinary Incontinence", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Percentage of participants who are 100% incontinence-free/dry", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767519"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants with positive response on the single-item Treatment Benefit Scale", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of micturition episodes", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of Nocturia Episodes", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "King's Health Questionnaire Role and Social Limitation Domain Scores", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}